XAIR vs. ZYXI, ICCM, CTSO, NTRB, VANI, INO, MBOT, EDAP, HYPR, and GUTS
Should you be buying Beyond Air stock or one of its competitors? The main competitors of Beyond Air include Zynex (ZYXI), IceCure Medical (ICCM), Cytosorbents (CTSO), Nutriband (NTRB), Vivani Medical (VANI), Inovio Pharmaceuticals (INO), Microbot Medical (MBOT), Edap Tms (EDAP), Hyperfine (HYPR), and Fractyl Health (GUTS). These companies are all part of the "medical equipment" industry.
Beyond Air vs.
Zynex (NASDAQ:ZYXI) and Beyond Air (NASDAQ:XAIR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation, community ranking and risk.
Zynex has higher revenue and earnings than Beyond Air. Beyond Air is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.
In the previous week, Zynex had 25 more articles in the media than Beyond Air. MarketBeat recorded 28 mentions for Zynex and 3 mentions for Beyond Air. Beyond Air's average media sentiment score of 0.17 beat Zynex's score of 0.03 indicating that Beyond Air is being referred to more favorably in the news media.
Zynex has a net margin of 2.49% compared to Beyond Air's net margin of -1,730.00%. Zynex's return on equity of 13.05% beat Beyond Air's return on equity.
Beyond Air received 18 more outperform votes than Zynex when rated by MarketBeat users. Likewise, 69.57% of users gave Beyond Air an outperform vote while only 55.56% of users gave Zynex an outperform vote.
29.7% of Zynex shares are owned by institutional investors. Comparatively, 31.5% of Beyond Air shares are owned by institutional investors. 52.1% of Zynex shares are owned by company insiders. Comparatively, 20.1% of Beyond Air shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Zynex has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Beyond Air has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500.
Zynex currently has a consensus target price of $10.25, indicating a potential upside of 370.18%. Beyond Air has a consensus target price of $3.67, indicating a potential upside of 1,430.33%. Given Beyond Air's stronger consensus rating and higher possible upside, analysts plainly believe Beyond Air is more favorable than Zynex.
Summary
Zynex beats Beyond Air on 10 of the 19 factors compared between the two stocks.
Get Beyond Air News Delivered to You Automatically
Sign up to receive the latest news and ratings for XAIR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Beyond Air Competitors List
Related Companies and Tools
This page (NASDAQ:XAIR) was last updated on 4/18/2025 by MarketBeat.com Staff
Buy XAIR Stock Free XAIR Stock Alerts